GIM
NGNE icon

Granahan Investment Management’s Neurogene NGNE Stock Holding History

Granahan Investment Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,267
Closed -$906K – 191
2021
Q3 		$906K Sell
6,267
-3,487
-36% -$534K 0.02% 188
2021
Q2 		$1.8M Sell
9,754
-272
-3% -$60.2K 0.03% 181
2021
Q1 		$2.47M Sell
10,026
-2,289
-19% -$585K 0.05% 166
2020
Q4 		$3.47M Sell
12,315
-2,511
-17% -$614K 0.08% 152
2020
Q3 		$3.56M Buy
14,826
+1,086
+8% +$263K 0.12% 125
2020
Q2 		$4.56M Buy
+13,740
New +$3.58M 0.16% 110

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Granahan Investment Management's NGNE Position: Q4 2021 in Review

Granahan Investment Management sold out of Neurogene (NGNE) in Q4 2021, closing a stake of 6,267 shares — an estimated $906K sold.

Granahan Investment Management first reported a position in NGNE in Q2 2020 and held it in 6 quarters. The position peaked at $4.56M in Q2 2020. 80 funds tracked by Wall St. Rank hold NGNE as of Q4 2021.

  • Granahan Investment Management reported no remaining Neurogene position as of Q4 2021 after selling out during the quarter.
  • Granahan Investment Management sold 6,267 Neurogene shares in Q4 2021, an estimated $906K.
  • Granahan Investment Management first reported a position in Neurogene in Q2 2020 and held it in 6 quarters.
  • Granahan Investment Management's Neurogene position peaked at $4.56M in Q2 2020.
  • 80 funds tracked by Wall St. Rank held Neurogene as of Q4 2021.

Based on Granahan Investment Management's 13F filing for Q4 2021, filed 14 Feb 2022.